PDS biotechnology's Versamune platform is based on novel and proprietary synthetic cationic lipids, which promote critical intra-cellular delivery of tumor-related antigens and activate important immunologic signaling pathways that induce effective priming and proliferation of critical populations of killer T-cells
able specifically to attack and kill cancerous cells.
These killer T-Cells
are assisted by helper T-Cells that coordinate the attack and send chemical messages asking the killer T-Cells
(cytotoxic T-lymphocytes) attack pathogenic cells and are particularly useful for fighting viruses.
This CAR-T technology is initially focused on ovarian cancer, by engineering killer T-cells
with the follicle stimulating hormone (FSH) to target ovarian cells that express the FSH-receptor.
In tests on mouse cells, the researchers found that when cancer cells are stressed by an experimental anti-CD47 immunotherapy, the cancer cells leak DNA into nearby dendritic cells, which present antigens to killer T-cells
and are considered a bridge between the innate and adaptive immune systems.
Fortunately, scientists have discovered a substance called undenatured type II collagen, or UC-II[R], that retrains killer T-cells
(which destroy target cells) so that they recognize collagen as a harmless substance--preventing the joint damage seen in osteoarthritis.
The cells are modified by adding a natural killer t-cell
ligand, which permits them to stimulate natural killer T-cells
, along with an antigen associated with a cancer.
T-cells secrete cytokines that direct activity of other immune cells (helper T-cells), recognise and destroy virus-infected body cells (killer T-cells
) and prevent the immune system from over-reacting (regulatory T-cells).
are an important component of our immune system.
The researchers want to make a vaccine from a component of the early killer T-cells
It also produces killer T-cells
that eliminate infected cells.